Mounjaro Becomes India’s Top-Selling Drug by Revenue in October, Outpaces Wegovy by Tenfold in Volume

Updated: November 07, 2025 10:56

Image Source : Business Today

Eli Lilly’s Mounjaro surged to become India's highest-selling drug by revenue in October 2025, clocking nearly ₹100 crore in monthly sales. Its volume consumption is ten times that of competitor Wegovy, reflecting strong market demand fueled by a dual indication for diabetes and weight loss and aggressive marketing.

Key Highlights

Mounjaro achieves nearly ₹100 crore in October 2025 sales, marking a 25% month-on-month growth
Surpasses GSK’s Augmentin to become India's top-selling pharmaceutical brand by value
Volume sales in India are 10 times higher than competitor Wegovy for October
Launched in India in March 2025, cumulative revenue reached ₹333 crore by October
Growth driven by user-friendly pen formulation, expanded reach through partnership with Cipla (Yurpeak)
GST rate cut from 18% to 5% reduced therapy costs, increasing treatment affordability
Mounjaro targets diabetes and obesity, addressing India’s substantial overweight population
Analysts predict sales could stabilize near ₹2,000 crore annually as demand continues
Wegovy lags due to later launch and leaner market penetration

Detailed Report

Eli Lilly’s Mounjaro, a groundbreaking antidiabetic and anti-obesity medication, has astonishingly become the best-selling drug in India by revenue for October 2025, nearly hitting ₹100 crore in monthly sales, according to Pharmarack data. This growth represents a substantial 25% increase from September, driven by enhanced doctor outreach, cost reductions from GST cuts, and the drug’s simpler, patient-friendly prefilled pen devices.

Mounjaro’s volume sales eclipsed its closest rival, Novo Nordisk’s Wegovy, by a factor of ten for the month, showcasing the drug’s dominant position in the burgeoning market for metabolic disorder treatments. Since its launch just seven months ago in March, the drug has amassed ₹333 crore in cumulative revenue—a striking achievement on the rapidly evolving Indian pharmaceutical landscape.

Market experts highlight the dual therapeutic advantage of Mounjaro, prescribed for both type 2 diabetes and obesity, in a country grappling with one of the world’s largest overweight populations. The strategic alliance with Cipla to manufacture and market the drug as Yurpeak has expanded its reach in metro and non-metro regions alike.

With sales momentum unrelenting, industry analysts foresee Mounjaro’s annual sales climbing towards the Rs 2,000 crore mark, potentially reshaping India’s prescription drug market with faster adoption and broader treatment coverage.

Sources: Moneycontrol, Economic Times, Business Standard, Pharmarack

Stay Ahead – Explore Now! Navigating Success: Knowledge Marine Engineers a Rs 1.27 Bn Boost in Inland Waterways